Here's Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity

Danaher stock declined 12.1% this week despite beating Q2 earnings estimates and raising full-year EPS guidance. The sell-off was triggered by the revelation that most of the guidance increase ($0.07-$0.08) comes from the Masimo acquisition rather than organic growth, and by reduced biotechnology sales growth expectations due to timing shifts in consumables shipments. The article suggests the market overreacted, as shipment delays in biotech are typically temporary.